



The EDI (Experimentelle Diagnostische Immunologie) GmbH was founded in 1996 and is a certified (EN ISO 13485) research company, offering services within the field of immuno pharmacology and immuno toxicology. In 2007, EDI GmbH merged with Rules-Based Medicine ("RBM"), Austin, TX, USA, one of the leading biomarker companies. The marker panels developed by RBM present the largest multi analyte profil capability for proteins. Miniaturized and parallelized sandwich immunoassays, e.g. Multi-Analyte Profiling tests are highly sensitive assay-systems that allow the accurate quantification of a large number of target proteins in body fluids from minute amounts of samples. At EDI/RBM more than 200 marker proteins can be analyzed in human plasma using miniaturized and multiplexed sandwich immunoassays. Recently, RBM launched the Human Kidney Multi-Analyte Profiling, which can be used in clinical trials to reveal early signs and locations of drug-induced kidney damage, known as renal toxicity or nephrotoxicity, thereby guiding important decisions on lead compounds and dosage.

<http://www.edigmbh.de> | [www.rulesbasedmedicine.com](http://www.rulesbasedmedicine.com)